Afuco™ Anti-Human BST2 ADCC Therapeutic Antibody (XmAb 5592), ADCC Enhanced
Anti-BST2 ADCC Enhanced Antibody (XmAb 5592) is an ADCC enhanced antibody produced by our Afuco™ platform. XmAb5592, a humanized anti-HM1. 24 mAb with Fc-domain engineered to significantly enhance FcγR binding and associated immune effector functions. The clinical development of XmAb5592, both as a monotherapy and in combination with lenalidomide, to improve patient outcome of multiple myeloma (MM).
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-072CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | BST2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples. |